BiotechTube
Home/Pipeline/PATHFINDER 2

PATHFINDER 2

Multi-Cancer Early Detection

Interventional StudyActive

Key Facts

Indication
Multi-Cancer Early Detection
Phase
Interventional Study
Status
Active
Company
GRAIL

About GRAIL

GRAIL's mission is to alleviate the global burden of cancer through early detection. The company has achieved a leading position in the MCED space with its Galleri test, supported by a robust clinical program involving over 385,000 participants, including landmark trials like NHS-Galleri. Its strategy centers on generating definitive clinical evidence to drive widespread adoption, secure reimbursement, and integrate its test into routine clinical care for adults at elevated risk.

View full company profile

Therapeutic Areas

Oncology

Other Multi-Cancer Early Detection Drugs

DrugCompanyPhase
ALMANAC StudyGuardant HealthResearch
Ausel Cancer TestAusel Cancer InnovationPre-clinical
GAGome for MCEDElyptaClinical Validation
Rivela MCED TestEXOSOMICSPre-clinical
CancerGuard™Exact SciencesPivotal Studies
REACH/Galleri-Medicare StudyGRAILProspective Cohort Study
REFLECTION StudyGRAILObservational Study
SUMMIT StudyGRAILObservational Cohort Study
PATHFINDER StudyGRAILInterventional Study
MCED TestMainz BiomedResearch Collaboration